Role of common-g chain cytokines in NK cell development and function: perspectives for immunotherapy, J Biomed Biotechnol, p.861920, 2011. ,
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix, Blood, vol.99, pp.1659-65, 2002. ,
Managing toxicities of high-dose interleukin-2, Oncology, vol.16, pp.11-20, 2002. ,
Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature, Nat Biotechnol, vol.20, pp.264-273, 2002. ,
Immunocytokines: a novel class of potent armed antibodies, Drug Discov Today, vol.17, pp.583-90, 2012. ,
Antibody-cytokine fusion proteins, Arch Biochem Biophys, vol.526, pp.194-205, 2012. ,
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma, Eur J Cancer, vol.46, pp.2926-2961, 2010. ,
Phase I study of ch14.18 with granulocytemacrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group, J Clin Oncol, vol.27, pp.85-91, 2009. ,
Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome, Proc Natl Acad Sci, vol.96, pp.3957-62, 1999. ,
Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2, Cell Immunol, vol.165, pp.289-93, 1995. ,
Interleukin-15 biology and its therapeutic implications in cancer, Trends Pharmacol Sci, vol.33, pp.35-41, 2012. ,
IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2, J Leukoc Biol, vol.57, pp.763-769, 1995. ,
Functional characterization of the human interleukin-15 receptor a chain and close linkage of IL15RA and IL2RA genes, J Biol Chem, vol.270, pp.29862-29871, 1995. ,
Identification and cloning of a novel IL-15 binding protein that is structurally related to the a chain of the IL-2 receptor, EMBO J, vol.14, pp.3654-63, 1995. ,
IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice, Proc Natl Acad Sci, vol.97, pp.11445-50, 2000. ,
Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy, Immunity, vol.14, pp.105-115, 2001. ,
Safety and immunologic effects of IL-15 administration in nonhuman primates, Blood, vol.114, pp.2417-2443, 2009. ,
Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice, J Exp Med, vol.191, pp.771-80, 2000. ,
T cellindependent interleukin 15Ra signals are required for bystander proliferation, J Exp Med, vol.194, pp.1187-94, 2001. ,
IL-15 and IL-2: a matter of life and death for T cells in vivo, Nat Med, vol.7, pp.114-132, 2001. ,
IL-15Ra recycles and presents IL-15 in trans to neighboring cells, Immunity, vol.17, pp.537-584, 2002. ,
Coordinate expression and trans presentation of interleukin (IL)215Ra and IL-15 supports natural killer cell and memory CD81 T cell homeostasis, J Exp Med, vol.200, pp.825-859, 2004. ,
Macrophage-and dendritic-cell-derived interleukin-15 receptor a supports homeostasis of distinct CD81 T cell subsets, Immunity, vol.31, pp.811-833, 2009. ,
Natural, proteolytic release of a soluble form of human IL-15 receptor a-chain that behaves as a specific, high affinity IL-15 antagonist, J Immunol, vol.173, pp.1681-1689, 2004. ,
URL : https://hal.archives-ouvertes.fr/inserm-02437358
Preassociation of IL-15 with IL-15R a-IgG1-Fc enhances its activity on proliferation of NK and CD81/CD44 high T cells and its antitumor action, J Immunol, vol.180, pp.2099-106, 2008. ,
Interleukin-15/interleukin-15R a complexes promote destruction of established tumors by reviving tumor-resident CD81 T cells, Cancer Res, vol.68, pp.2972-83, 2008. ,
Combined IL-15/IL-15Ra immunotherapy maximizes IL-15 activity in vivo, J Immunol, vol.177, pp.6072-80, 2006. ,
Soluble interleukin-15 receptor a (IL-15R a)-sushi as a selective and potent agonist of IL-15 action through IL-15R b/g. Hyperagonist IL-15 3 IL-15R a fusion proteins, J Biol Chem, vol.281, pp.1612-1631, 2006. ,
The exon-3-encoded domain of IL-15ra contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ra, J Mol Biol, vol.382, pp.1-12, 2008. ,
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo, J Exp Med, vol.206, pp.25-34, 2009. ,
High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor a fusion protein, in metastatic melanoma and colorectal cancer, Mol Cancer Ther, vol.8, pp.2736-2781, 2009. ,
Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2, Proc Natl Acad Sci, vol.79, pp.7629-7662, 1982. ,
Pathogenesis of the neurotoxicity caused by anti-GD2 antibody therapy, J Neurol Sci, vol.149, pp.127-157, 1997. ,
Membrane lipids of adult human brain: lipid composition of frontal and temporal lobe in subjects of age 20 to 100 years, J Neurochem, vol.63, pp.1802-1813, 1994. ,
Role of tumorassociated gangliosides in cancer progression, Biochimie, vol.85, pp.455-63, 2003. ,
Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody, J Immunol, vol.144, pp.1382-1388, 1990. ,
Complementmediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer, Cancer Res, vol.65, pp.10562-10570, 2005. ,
The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research, Clin Cancer Res, vol.15, pp.5323-5360, 2009. ,
A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma, Eur J Cancer, vol.31, pp.261-268, 1995. ,
Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen, Clin Cancer Res, vol.13, pp.5613-5620, 2007. ,
Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus, Blood, vol.70, pp.1069-72, 1987. ,
Heterodimerization of the IL-2 receptor b-and g-chain cytoplasmic domains is required for signalling, Nature, vol.369, pp.330-333, 1994. ,
Different dynamics of IL-15R activation following IL-15 cis-or trans-presentation, Eur Cytokine Netw, vol.21, pp.297-307, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-02437096
Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice, Cancer Immunol Immunother, vol.48, pp.219-248, 1999. ,
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat Med, vol.6, pp.443-449, 2000. ,
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model, Clin Cancer Res, vol.9, pp.5866-73, 2003. ,
Properties of mouse and human IgG receptors and their contribution to disease models, Blood, vol.119, pp.5640-5649, 2012. ,
Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity, Cytokine, vol.20, pp.121-130, 2002. ,
Inhibition of tumor growth by NK1.11 cells and CD81 T cells activated by IL-15 through receptor b/ common g signaling in trans, J Immunol, vol.181, pp.8237-8284, 2008. ,
An antibody fusion protein for cancer immunotherapy mimicking IL-15 transpresentation at the tumor site, Mol Cancer Ther, vol.11, pp.1279-88, 2012. ,